Quinuclidine derivatives and medicinal compositions containing the same
View Patent ↗Provided is an aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
1. An aerosol container comprising a powder inhalant comprising 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane wherein an anion X − is associated with the positive charge of the nitrogen atom and wherein X − is a pharmaceutically acceptable anion of a mono- or polyvalent acid.
2. The aerosol container of claim 1 , wherein the powder inhalant further comprises a pharmaceutically acceptable carrier or diluent.
3. The aerosol container of claim 2 , wherein the pharmaceutically acceptable carrier or diluent of the powder inhalant is lactose.
4. The aerosol container of claim 1 , wherein the powder inhalant further comprises a β 2 agonist.
5. The aerosol container of claim 4 , wherein the powder inhalant further comprises a steroid or a phosphodiesterase IV inhibitor.
6. The aerosol container of claim 1 , wherein the powder inhalant further comprises a steroid.
7. The aerosol container of claim 6 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.
8. The aerosol container of claim 1 , wherein the powder inhalant further comprises a phosphodiesterase IV inhibitor.
9. A method for treating chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis which method comprises use of an aerosol container of claim 1 to administer to a human or animal patient in need of such treatment an effective amount of the powder inhalant of claim 1 .
10. The method of claim 9 further comprising administering an effective amount of a β 2 agonist.
11. The method of claim 10 further comprising administering an effective amount of a steroid or a phosphodiesterase IV inhibitor.
12. The method of claim 9 further comprising administering an effective amount of a steroid.
13. The method of claim 12 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.
14. The method of claim 9 further comprising administering an effective amount of a phosphodiesterase IV inhibitor.